Zobrazeno 1 - 10
of 22
pro vyhledávání: '"11"'
Autor:
Bradford B. Worrall, Natalia S. Rost, Sunaina Yadav, Christopher R Levi, Theresa Tran, Pankaj Sharma, Paul Bentley, Nazeeha Hasan, James F. Meschia, Ioana Cotlarciuc
Publikováno v:
Journal of Neurology, Neurosurgery, and Psychiatry
Background White matter hyperintensities (WMH) are a common radiographic finding and may be a useful endophenotype for small vessel diseases. Given high heritability of WMH, we hypothesised that certain genotypes may predispose individuals to these l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7a0e3b3f1e67911f23f36b51335cb2f
http://hdl.handle.net/10044/1/40664
http://hdl.handle.net/10044/1/40664
Autor:
Jason Shiers, Kate Anderton, Kristopher Clark, Nicola Ternette, Martin Quibell, Peter Joyce, Carmen Tong, Jessica Sette, Wayne Paes, Andrew Leishman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundClinical data demonstrates increased antigen presentation diversity is an important factor in determining response rates to checkpoint inhibitors.1 In addition to tumor mutational burden, increased HLA heterozygosity and HLA evolutionary di
Autor:
Tian-Hui Guo, Xizhi Wen, Lujun Shen, Dongchun Hong, Wei-Jun Fan, Xiao-Long Zhang, Yizhuo Zhang, Qiu-Zhong Pan, Xiao-Hui Niu, Xing Zhang, Bu-Shu Xu, De-Sheng Weng, Jing Jing Zhao, Yi Que, Penghui Zhou, Huoying Chen, Wei Xiao, Zexian Liu, Hai-Rong Xu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThe advent of immune checkpoint therapy has been a tremendous advance in cancer treatment. However, the responses are still insufficient in patients with soft tissue sarcoma (STS). We aimed to identify rational combinations to increase the
Autor:
Marta Zalacain, Marta M. Alonso, Javier Martinez, Guillermo Herrador Cañete, Sara Labiano, Cristian Smerdou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundOsteosarcoma is an aggressive bone tumor, primarily arising in the pediatric age. Despite years of intensive research, outcome for metastatic and non-responder patients is very poor and has not improved in the last 30 years. These tumors ha
Autor:
Ileana S. Mauldin, Alejandro A. Gru, Max O. Meneveau, Adela Mahmutovic, Alexandra W. Hickman, Craig L. Slingluff, Kevin R. Lynch, Victor H. Engelhard, Nolan A. Wages, Samuel Young, Anne M. Stowman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundTertiary lymphoid structures (TLS) are ectopic lymphoid organs that are localized near tumors and other sites of inflammation, and are commonly believed to support antitumor immunity. We previously published studies that show that most desm
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
ObjectiveMucosal-associated invariant T (MAIT) cells are innate T cells with immunoregulatory activity and were recently found to be associated with various tumor types. The role of intrasinusoidal MAIT cells in hepatocellular carcinoma (HCC) has not
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundMerkel cell carcinoma (MCC) is a rare skin cancer with 46% disease-associated mortality and half of patients unresponsive to immune checkpoint inhibitors.1 2 MCC and melanomas often display decreased MHC class I (MHC-I) expression on the su
Autor:
Emilie Gauthy, Nancy Ramelot, Isabelle Gennart, Laure Twyffels, Eytan Breman, Fanny Huberty, Amelie Velghe, Hannes Iserentant, Benjamin Violle, Ann-Sophie Walravens, David E. Gilham, Thuy Nguyen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundWhilst delivering impressive clinical efficacy in certain hematological malignancies, Chimeric Antigen Receptor (CAR) T cell therapy has yet to deliver significant clinical impact across a broader array of cancer indications. Armoring CAR T
T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Toll-like receptors (TLRs) are evolutionarily conserved molecules that specifically recognize common microbial patterns, and have a critical role in innate and adaptive immunity. Although TLRs are highly expressed by innate immune cells, particularly
Autor:
Sunandan Saha, Rachel A. Burga, Meghan Langley, Michelle Ols, Jack Tremblay, Stanley Tam, Jeremy Hatem Tchaicha, Benjamin Primack, Colleen Foley, Gabriel Helmlinger, Theresa Ross, Sethi Dhruv Kam, Emily Brideau, Shyam Subramanian, Alonso Villasmil Ocando, Kyle Pedro, Mithun Khattar, Scott Lajoie, Gary Vanasse, Dan Thornton, Jan ter Meulen, Gwen Wilmes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAdoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has demonstrated tremendous promise in clinical trials for patients with solid or metastatic tumors.1 However, current TIL therapy requires systemic administration of IL-2 to